Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

PHASE3RecruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Lung Cancer

Interventions

DRUG

Toluenesulfonamide (PTS) Intratumoral Injection

intratumoral injection of toluenesulfonamide(PTS) to oligo lesions

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors

lead

Zhou Chengzhi

OTHER